VINAY K. PUDUVALLI
![](http://www.evecon.com.br/bandeiras/eua.gif)
Dr. Puduvalli is Professor and Chair within the Department of Neuro-Oncology. He is actively involved in patient care, clinical trials, basic and translational science laboratory interests. His clinical effort is directed towards developing novel therapies for patients with primary brain tumors and specifically malignant gliomas. He is the principal investigator of several clinical trials directed against these tumors.
Confira a agenda de atividades
23 DE MARÇO | SÁBADO
Room 1
10:50-12:00
PLENARY SESSION 3
Opening Session
Tumor Treating Fields: current role and future directions
Vaccines and IDHwt gliomas: prospects on the horizon
DNA methilation profiling as a model for precision diagnosis in neurooncology
Moderator: Guilherme Carvalhal Ribas (SP)
Moderator: Cleiton Formentin (SP)
Moderator: Roberto Abramoff (SP)
Opening Session
Tumor Treating Fields: current role and future directions
Speaker: Roger Stüpp (Estados Unidos)
Vaccines and IDHwt gliomas: prospects on the horizon
Speaker: Vinay K. Puduvalli (Estados Unidos)
DNA methilation profiling as a model for precision diagnosis in neurooncology
Speaker: Martha Quezado (Estados Unidos)
13:30-15:30
SESSION 4: DIFFUSE GLIOMAS
A Critical Overview of Targeted Therapies for Glioma
Translational research for gliomas: future landscapes and emerging paradigm
The role of CAR T cell therapy in neurooncology
What we do know about non-standard of care treatments for gliomas: cannabis, antidepressants, metformin and others
Bevacizumab, is there still a role for antiangiogenics in glioblastoma?
The optimal timing of palliative care in glioma patients
How feasible is surgery in the motor area?
Discussion
Moderator: ícaro Thiago de Carvalho (SP)
A Critical Overview of Targeted Therapies for Glioma
Speaker: Tracy Batchelor (Estados Unidos)
Translational research for gliomas: future landscapes and emerging paradigm
Speaker: Vinay K. Puduvalli (Estados Unidos)
The role of CAR T cell therapy in neurooncology
Speaker: Andreas Hottinger (Suíça)
What we do know about non-standard of care treatments for gliomas: cannabis, antidepressants, metformin and others
Speaker: Yvonne Kew (Estados Unidos)
Bevacizumab, is there still a role for antiangiogenics in glioblastoma?
Speaker: Juan Sepulveda (Espanha)
The optimal timing of palliative care in glioma patients
Speaker: Daniel Neves Forte (SP)
How feasible is surgery in the motor area?
Speaker: Lorenzo Bello (Itália)
Discussion